- Research
- Open access
- Published:
It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis
Respiratory Research volume 25, Article number: 345 (2024)
Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant lung epithelial phenotypes, fibroblast activation, and increased extracellular matrix deposition. Transforming growth factor-beta (TGF-β)1-induced Smad signaling and downregulation of peroxisomal genes are involved in the pathogenesis and can be inhibited by peroxisome proliferator-activated receptor (PPAR)-α activation. However, the three PPARs, that is PPAR-α, PPAR-β/δ, and PPAR-γ, are known to interact in a complex crosstalk.
Methods
To mimic the pathogenesis of lung fibrosis, primary lung fibroblasts from control and IPF patients with comparable levels of all three PPARs were treated with TGF-β1 for 24 h, followed by the addition of PPAR ligands either alone or in combination for another 24 h. Fibrosis markers (intra- and extracellular collagen levels, expression and activity of matrix metalloproteinases) and peroxisomal biogenesis and metabolism (gene expression of peroxisomal biogenesis and matrix proteins, protein levels of PEX13 and catalase, targeted and untargeted lipidomic profiles) were analyzed after TGF-β1 treatment and the effects of the PPAR ligands were investigated.
Results
TGF-β1 induced the expected phenotype; e.g. it increased the intra- and extracellular collagen levels and decreased peroxisomal biogenesis and metabolism. Agonists of different PPARs reversed TGF-β1-induced fibrosis even when given 24 h after TGF-β1. The effects included the reversals of (1) the increase in collagen production by repressing COL1A2 promoter activity (through PPAR-β/δ activation); (2) the reduced activity of matrix metalloproteinases (through PPAR-β/δ activation); (3) the decrease in peroxisomal biogenesis and lipid metabolism (through PPAR-γ activation); and (4) the decrease in catalase protein levels in control (through PPAR-γ activation) and IPF (through a combined activation of PPAR-β/δ and PPAR-γ) fibroblasts. Further experiments to explore the role of catalase showed that an overexpression of catalase protein reduced collagen production. Additionally, the beneficial effect of PPAR-γ but not of PPAR-β/δ activation on collagen synthesis depended on catalase activity and was thus redox-sensitive.
Conclusion
Our data provide evidence that IPF patients may benefit from a combined activation of PPAR-β/δ and PPAR-γ.
Background
IPF is a severe restrictive interstitial lung disease with patient median survival of 2.5–3.5 years [1]. Concerning the pathogenesis of IPF, it is being discussed that an excessive injury response results in persistent overproduction of extracellular matrix (ECM) components by activated and proliferating fibroblasts. In addition, oxidative stress remains a major mechanism associated with the progression of this disease [2]. Today, only limited treatment options for IPF are available. Evidence-based recommendations for the pharmacological management of the disease are the tyrosine kinase inhibitor nintedanib [3, 4] and pirfenidone [4, 5], an inhibitor of TGF-β1-stimulated collagen synthesis. Both drugs increase quality of life, attenuate symptoms and slow down IPF progression, but only nintedanib influences mortality. Some of the novel medications targeted pentraxin (involved in endogenous tissue repair), lysophosphatidic acid, or connective tissue growth factor (mediates TGF-β1 downstream signaling), but failed the clinical endpoints [6, 7]. Other substances in the pipeline are nerandomilast (a tyrosine kinase inhibitor) which successfully completed phase II clinical trials [8] and inhaled treprostinil, a prostacyclin analogue. Treprostinil showed beneficial effects in the initial INCREASE trial [9] and ongoing TETON study [10] and has meanwhile been approved for the therapy of WHO group 1 pulmonary hypertension with an additional positive impact in IPF. Nevertheless, extensive research is still required to develop new therapeutic modalities.
To find therapeutic interventions for IPF, several studies explored the anti-fibrotic potentials of natural and synthetic PPAR ligands. For example, PPAR-α activation was demonstrated to attenuate fibrosis in the liver [11], heart [12] and lung [13, 14], while PPAR-β agonists exhibited anti-proliferative effects [15], but increased the secretion of TGF-β1 and ECM [16]. Ligands of PPAR-γ are most promising [17,18,19,20] and were thought to inhibit fibroblast trans-differentiation [21, 22] and to strengthen the anti-oxidative defense system [23]. In addition, pan-PPAR agonists, such as lanifibranor [24] and IVA337 [25] attenuated fibrosis. In all these studies, however, the anti-fibrotic mechanism of PPAR agonists remained unclear and was supposed to be mainly due to their anti-inflammatory activities [26]. Another drawback was the time schedule of the drug treatment. Typically, drugs were added before or together with TGF-β1, but these approaches do not reflect the patient situation where drugs can be given only after the diagnosis of the disease, years after its initiation. In two studies, PPAR-γ agonists were applied after bleomyin-induced lung injury in the mouse. Zeng et al. [27] added the PPARγ ligand asarinin 15–28 days after bleomycin administration, which reduced the severity of fibrosis. Speca et al. [22] applied GED-0507, a PPARγ modulator with strong anti-inflammatory effects, to mice on day 14 after bleomycin administration and reported resolution of fibrosis with 50% mortality rate. This post-treatment schedule reduced collagen deposition, but to a lesser extent than in the prevention approach used in the same study. Thus, we thought that a post-treatment with a combination of PPAR ligands may further increase the anti-fibrotic effect. Moreover, we aimed to use a human model and human cultured fibroblasts as the latter in vitro model better guaranties the drug availability and allows a selective (biochemical) analysis of changes in fibroblasts, the main players in fibrosis.
In this study, we investigated whether activation of each of the three PPARs alone or in various combinations influenced collagen synthesis and release of lung fibroblasts from control and IPF patients when given 24 h after TGF-β1, the endogenous stimulator of fibrosis. Moreover, we attempted to explore the mechanism of the anti-fibrotic effect of PPAR agonists by analyzing changes in members of matrix metalloproteinases (MMPs) [28], biogenesis and metabolism of peroxisomes [13, 14], and the protein level and activity of catalase, the major anti-oxidative enzyme in peroxisomes [29] with the highest turnover numbers of all enzymes [30].
Methods
Study approval
Biospecimen collection (i.e. lung tissues and fibroblasts from organ donors) was approved by the Ethics Committee of the Justus Liebig University Giessen (Az58/15 and Az111/08, JLU).
Cell culture and drug treatment
Lung fibroblasts from control and IPF patients (Additional file: Table S1) and catalase-deficient fibroblast cell lines were cultured in Dulbecco´s Modified Eagle Medium (DMEM) with penicillin/streptomycin or puromycin, respectively. For the experiments, cells were serum-starved for 3 h, stimulated with vehicle or rhTGF-β1 for 24 h (except for Figs. 2B, C, E, 3B), followed by the addition of vehicle or drugs either alone or in combinations for another 24 h.
Knockdown of catalase in human lung fibroblasts
Knockdown of catalase was done with CAT siRNA using ScreenFectA transfection reagent. Stable catalase knockdown was achieved by transduction with pGIPZ-shCatalase and pGIPZ-non-silencing control lentivirus vectors as described earlier [31].
Overexpression of catalase in human lung fibroblasts
Transfection with catalase overexpression plasmid (pGL 4.14-Catalase) and promoter reporter plasmids COL1A2-luc and PPAR response element (PPRE)-luc were done as described earlier [13, 32]. Data from pRL-SV40 vector served to normalize results of the luciferase reporter plasmid.
Human TGF-β1 immunoassay and sircol collagen assay
The collected culture media of control and IPF fibroblasts were used for Sircol collagen assays and TGF-β1 ELISA assay according to the manufacturers´ instructions.
Measurements of catalase activity, hydrogen peroxide (H2O2) production and cell proliferation
Determination of catalase activity with a redox dye assay kit based on the degradation of H2O2. H2O2 produced by cultured cells was quantified using a fluorometric detection kit. The incorporation of BrdU into proliferating cells was detected with an ELISA kit. For all the aforementioned kits, we followed the manufacturers´ instructions.
Western blotting
Proteins of total cell lysates were separated on 10% SDS-PAGE gels and blotted on polyvinylidene difluoride membranes. Specific proteins were detected using primary and horseradish peroxidase (HRP)-labelled secondary antibodies followed by chemiluminescent detection of the HRP substrate. ImageJ was used for semi-quantitative analysis of signal intensities.
Immunofluorescence staining
Thin sections of paraffin-embedded lung tissues were incubated with primary and secondary fluorophore-labelled antibodies. Immunofluorescence images were acquired by confocal laser scanning microscopy.
Isolation of total RNA and RT-qPCR
Total RNA was isolated using RNAzol and mRNA levels were analyzed by RT-qPCR.
Targeted quantification of fatty acids
Arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) were analyzed in the culture medium by solid phase extraction and a targeted liquid chromatography tandem mass spectrometry (LC–MS/MS) approach as described previously [32].
Untargeted lipidomics
Lipids were extracted from cell lysates using a biphasic methyl-tert-butyl ether (MTBE) extraction protocol [33] and analyzed using an untargeted LC–MS/MS method as described previously [34].
Statistics
Analysis was done using GraphPad Prism software. Data were expressed as means ± SEM. For comparisons between two groups, the F-test was applied to compare their variances followed by Mann–Whitney U test (unequal variances) or unpaired t-test (equal variances). For multiple comparisons, ANOVA was used with post-hoc Tukey´s multiple comparisons test. P values < 0.05 were considered as statistically significant.
Results
Characterization of the fibrosis markers COL1 and α-SMA, as well as of PPARs in lung tissues and cultured fibroblasts from control and IPF patients
The fibrosis marker collagen type I (COL1) and myofibroblast marker α-smooth muscle actin (α-SMA) were first assessed in lung biopsy samples from control and IPF patients. Lung tissues from IPF patients showed comparatively higher levels of COL1 and α-SMA than those from control subjects (Fig. 1A). Although increased mRNA levels of COL1A1 and ACTA2 were detected in cultured lung fibroblasts from IPF compared to control patients (Additional file: Fig. S1A, B), their protein levels and that of transforming growth factor-beta receptor 1 (TGFBR1) were higher in most cases in fibroblasts from control compared to IPF patients (Additional file: Fig. S1C, Table 1). Although unexpected at first glance, it is noteworthy that IPF lung tissue contains a much higher number of fibroblasts than controls. Probably, the higher number of fibroblasts in the lungs of IPF patients and to a minor extent their individual properties contribute to the differences in tissue pathology. Moreover, the reduced level of TGFBR1 in IPF fibroblasts suggests that they are less sensitive to TGF-β1 presumably due to their chronic exposure to the cytokine in vivo. Accordingly, analysis of extracellular collagen revealed no significant difference between control and IPF fibroblasts (Fig. 1B, Additional file: Fig. S1D). IPF is characterized by elevated levels of TGF-β1 mRNA and protein in the lung tissues of patients [35, 36]. Interestingly, the amount of released active TGF-β1 was higher in the culture media from control than IPF fibroblasts (Fig. 1C). We demonstrated an anti-fibrotic role of peroxisomes in the progression of IPF via PPAR-α signaling [13, 14]. Since all three PPARs crosstalk with each other [37], we next analyzed their protein levels in fibroblasts from control and IPF patients at basal conditions (no treatment in vitro). Collectively, IPF fibroblasts showed increased mRNA and protein levels of PPAR-α, but not of the ones of PPAR-β/δ and PPAR-γ compared to control fibroblasts (Fig. 1D, Table 1, Additional file: Fig. S1E).
Activation of PPAR-β/δ induced anti-fibrotic responses in TGF-β1-stimulated fibroblasts from control and IPF patients
As already noted, the number of fibroblasts in the lungs of IPF patients might be crucial for the disease progression. To confirm this, we analyzed the proliferation of vehicle- and TGF-β1-treated control and IPF fibroblasts since the cytokine was used to mimic part of the disease condition in vitro. As expected, TGF-β1 stimulated cell proliferation in control and IPF fibroblasts (Fig. 2A). Next, we analyzed time-dependent changes in α-SMA and COL1 protein levels of control and IPF fibroblasts treated with TGF-β1. Control and IPF fibroblasts did not show differences after stimulation with different concentrations of TGF-β1 (2.5–20 ng/ml; Fig. 2B) in the extracellular collagen released into the culture media. Though 2.5 ng/ml of TGF-β1 was already sufficient to reach the maximal effect for collagen values 24 h after treatment (Fig. 2B), 5 ng/ml TGF-β1 was used to obtain maximal effects in all following experiments with distinct parameters. TGF-β1 increased intracellular COL1 and α-SMA protein levels from 12 to 48 h in control fibroblasts and from 24 h up to 48 h in IPF fibroblasts (Fig. 2C). Moreover, the treatment with TGFβ-1 for 24 h in control and IPF fibroblasts from 10 different patients showed a homogenous and stable increase in the protein levels of COL1, but an inconsistent reaction in the case of α-SMA (Fig. 2D, Table 1). To investigate the role of peroxisomes in IPF, their proliferation was induced using different PPAR ligands. Interestingly, TGF-β1 upregulated the protein level of PPAR-β/δ especially after 48 h of treatment (Fig. 2E). Following 24 h TGF-β1 stimulation, treatment with PPAR-β/δ agonist alone or in combination with the two other members of the PPAR protein family inhibited the TGF-β1-mediated increase in COL1 and—to a lesser extent—α-SMA protein levels in control and IPF fibroblasts (Fig. 3A). As already noted, anti-fibrotic properties of PPAR-γ have been reported in the past. In our study, the post-treatment with a PPAR-β/δ agonist (GW0742) alone or combined with a PPAR-γ agonist (rosiglitazone) strongly decreased the amount of TGF-β1-mediated increase in intracellular COL1 (Fig. 3A–C) by affecting COL1A2 promotor activity (Fig. 3D) as well as extracellular collagen (Fig. 3E) in both, fibroblasts from control and IPF patients. Lesser effects were observed in the case of activation of PPAR-γ alone (Fig. 3A, C, E). The decrease in the amount of COL1 as a result of the dual treatment of PPAR-β/δ and PPAR-γ agonists was stable over time (Fig. 3B) and between patients (Fig. 3C). Furthermore, the anti-fibrotic effects of a combined activation of PPAR-β/δ and PPAR-γ were blocked in the presence of PPAR-β/δ (GSK0660) and PPAR-γ (GW9662) antagonists (Fig. 3F). In addition, we thought to use the compound STK 648389 (ZINC ID: 31,775,965), a putative dual agonist for PPAR-β/δ and PPAR-γ. However, analysis of the STK 648389 for its effect on collagen showed adverse effects and even increased extracellular collagen levels released by control and IPF fibroblasts after TGF-β1 exposure (Additional file: Fig. S2). Altogether, these findings suggest that although TGF-β1 increases the PPAR-β/δ protein as a protective adaptive mechanism, endogenous PPAR-β/δ activating ligands are probably diminished to prevent fibrosis in patients.
PPAR-β/δ triggers anti-fibrotic responses by activating MMP-1 in control and IPF fibroblasts
Extracellular collagen is degraded by proteinases, e.g. MMPs. The mRNA levels of selected MMPs in control fibroblasts at basal condition (without treatment) were measured, showing the highest value for MMP1 in comparison to the lower mRNA values for MMP2, MMP3, MMP10, and MMP16 (Fig. 4A). Interestingly, the mRNA level of MMP7 which is associated with disease severity [28] was below detectable levels in our samples of control and IPF fibroblasts (ct values > 35). Comparing the mRNA levels between control and IPF fibroblasts, no differences were observed in the case of MMP1 and MMP16 (Fig. 4B, F), but higher levels were found for MMP2, MMP3 and MMP10 (Fig. 4C–E). Individual mRNA values for MMP1, but also for MMP3 and MMP10, varied strongly within the IPF sample group (Fig. 4B, D, E). Due to the much higher mRNA levels for MMP1 compared to the other MMPs (Fig. 4A), we analyzed MMP-1 protein as the dominant enzyme for collagen degradation in subsequent experiments. As expected, the protein level of active MMP-1 was reduced by TGF-β1 and restored in the presence of PPAR-β/δ agonist alone or in combination with PPAR-α or PPAR-γ agonists (Fig. 4G). This suggests that PPAR-β/δ might be a key regulator of the protein level of active MMP-1. Therefore, we analyzed the effect of the PPAR-β/δ agonist in TGF-β1-stimulated fibroblasts at the mRNA levels of all detectable MMPs. The mRNA levels of MMP1 in IPF fibroblast were increased (> fivefold) by the PPAR-β/δ agonist in comparison to TGF-β1 stimulation alone (Fig. 4H). The MMP16 mRNA levels were elevated > fivefold in both types of fibroblasts and that of MMP10 about threefold in control fibroblasts only (Additional file: Fig. S3). To explore the anti-fibrotic potential of increased levels of MMPs, we used a broad-spectrum inhibitor for MMPs, primarily influencing the amount of extracellular collagen. Simultaneous treatment with the MMP inhibitor and PPAR-β/δ agonist after TGF-β1 stimulation increased extracellular collagen in the culture media released by control fibroblasts, but not in the case of IPF fibroblasts (Fig. 4I). Since the MMP inhibitor only partly blocked the effect of the PPAR-β/δ agonist, we speculate that activated PPAR-β/δ also regulates other proteins involved in fibrosis attenuation.
Activation of PPAR-β/δ and PPAR-γ in TGF-β1-treated fibroblasts increased peroxisomal biogenesis and lipid metabolism, and the inhibited fibrotic response
Previously, we showed that pretreatment with PPAR-α agonists could inhibit fibrosis phenotypes [13, 14]. In the present study, we treated control and IPF fibroblasts with TGF-β1 before the addition of agonists of all three PPARs, an experimental setup that more accurately recapitulates the clinical setting. We first investigated the mRNA levels of several peroxisomal genes involved in the organelle biogenesis (PEX13, PEX14), plasmalogen synthesis (AGPS, GNPAT), and fatty acid β-oxidation (ACOX1, ACAA1) in control and IPF fibroblasts. The mRNA levels of PEX13, ACOX1 and AGPS were higher in IPF compared to control fibroblasts, whereas those of PEX14, ACAA1 and GNPAT were not significantly different (Additional file: Fig. S4A–F). Next, we stimulated peroxisomal proliferation with different PPAR agonists (alone or in combination) in TGF-β1-treated control and IPF fibroblasts. Combined activation of PPAR-β/δ and PPAR-γ increased mRNA (Additional file: Fig. S4G) and protein levels (Fig. 5A) of PEX13 in TGF-β1-stimulated control and IPF fibroblasts compared to TGF-β1 treatment only. Since the combined activation of PPAR-β/δ and PPAR-γ reversed the TGF-β1-induced trans-differentiation of fibroblasts into myofibroblasts (as indicated by changes in the level of α-SMA, Fig. 3A–C), decreased the protein level of COL1 (Fig. 3A–C) and increased PEX13 (Fig. 5A), we focused on these two PPAR agonists in the following experiments. First, the intracellular lipidomic profile was assessed in control and IPF fibroblasts to ascertain possible differences in the lipid metabolism under basal conditions and after treatments with TGF-β1 alone and PPAR-β/δ and PPAR-γ agonists. In total, 1003 lipid ion species covering 5 major lipid categories (glycerophospholipids, sphingolipids, glycerolipids, fatty acyls, and sterols) belonging to 22 lipid classes were identified based on high mass accuracy (5 ppm) and their fragmentation patterns (Additional file: Fig. S5A). Basal levels of all classes of lipids analyzed were lower in IPF fibroblasts except for the triglycerides (TG; Fig. 5B). TGF-β1 decreased the levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM) and TG in IPF fibroblasts. The levels of PC, SM and TG were partially restored by a post-treatment with PPAR-β/δ and PPAR-γ agonists (Fig. 5B). Furthermore, activation of PPAR-β/δ and PPAR-γ strongly increased the synthesis of peroxisome-derived AA, DHA, and EPA (Fig. 5C), which are all endogenous activators of PPARs. In the absence of TGF-β1, PPAR agonists either increased or decreased the levels of PC in control and IPF fibroblasts (Additional file: Fig. S5B) and increased the levels of AA, DHA and EPA with PPAR-γ exhibiting the strongest effect on DHA (Additional file: Fig. S5C). This suggests that, the PPAR-γ agonist was the driving factor for the increase and release of AA, DHA and EPA in fibroblasts treated with TGF-β1 followed by combined PPAR-β/δ and PPAR-γ agonists treatment (Fig. 5C). Collectively, activation of PPAR-β/δ and PPAR-γ potentially regulates the fibrosis phenotype by modulating peroxisomal lipid metabolism, but differently in control and IPF fibroblasts.
Activation of PPAR-β/δ in combination with PPAR-γ restored TGF-β1-induced decrease in catalase mRNA and protein levels
Though not significant, TGF-β1 decreased CAT mRNA level in control and IPF fibroblasts, which was restored by the combined activation of PPAR-β/δ and PPAR-γ (Additional file: Fig. S4G). We therefore speculated that this anti-oxidative enzyme might be involved in regulation of fibrogenesis. We first analyzed catalase and glutathione peroxidase (GPX)1/2 in human lung tissue samples. The protein level of catalase was markedly decreased in alveolar epithelial type II cells in the lungs of IPF compared to control patients (Fig. 6A), whereas that of GPX1/2 was increased (Fig. 6B), probably to compensate catalase deficiency. Moreover, we detected a gradual decrease in catalase protein level in mouse lungs after bleomycin-induced fibrosis, remarkably from day 14 after treatment (Additional file: Fig. S6A). When we analyzed the fibroblasts from control and IPF patients, we found no differences in the mRNA levels of CAT and GPX1/2 (Additional file: Fig. S6B, C). Protein level of catalase was lower in IPF compared to control fibroblasts (isolated from 5 patients each, Fig. 6C, Table 1). Apart from catalase and GPX1/2, peroxiredoxins (PRDXs) were measured as they also support the anti-oxidant defense system. The mRNA levels of different peroxiredoxin family members varied strongly (Additional file: Fig. S6D) with PRDX6 showing the highest and PRXD2 and PRXD3 the lowest gene expression levels. Only the mRNA levels of PRDX4 and PRDX6 were significantly higher in IPF compared to control fibroblasts (Additional file: Fig. S6E–J). To confirm the regulatory effects of TGF-β1 on catalase, we treated control and IPF fibroblasts with TGF-β1 at various concentrations. Increasing concentrations of TGF-β1 gradually decreased the protein level of catalase in both fibroblast groups (Fig. 6D). Catalase activity was reduced by TGF-β1 in control and IPF fibroblasts, but not in the same manner since IPF fibroblasts were less sensitive towards lower concentrations of TGF-β1 (2.5 and 5 ng/ml; Fig. 6E). Activation of PPAR-γ increased the protein level of catalase in the absence of TGF-β1 (Additional file: Fig. S6K) and reversed the TGF-β1-induced decrease in catalase in control fibroblasts (Fig. 6F). The level of catalase increased in both groups when PPAR-β/δ and PPAR-γ were activated 24 h after TGF-β1 treatment (Fig. 6F), but not when added together with TGF-β1 (Fig. 6G).
Catalase contributes to collagen reduction in pulmonary fibrosis
To confirm the anti-fibrotic role of catalase in IPF, we intended to generate stable catalase-deficient fibroblast cell lines by RNAi using two independent shRNAs against catalase (CAT sh1 RNA and CAT sh2 RNA). Knockdown efficiency of catalase was high and stable in control fibroblasts, whereas IPF fibroblasts died after a few passages probably because the catalase protein level was already low prior to shRNA transduction (see Fig. 6C) and a further decrease in this protein was detrimental. Successful reduction of catalase is shown on the protein (Fig. 7A) and activity (Fig. 7B) levels, resulting in an increase in H2O2 concentration (Fig. 7C). The decrease in catalase protein in control fibroblasts expressing either of the two independent catalase shRNAs was accompanied with increased extracellular collagen (Fig. 7D) and intracellular COL1 (Fig. 7A) levels. Using siRNA technology, a transient catalase knockdown was achieved in control and IPF fibroblasts (Additional file: Fig. S7A). In IPF fibroblasts, we detected higher levels of collagen released into the culture medium compared to those transfected with scrambled control siRNA (Additional file: Fig. S7B). Moreover, catalase overexpression in control and IPF fibroblasts decreased COL1 and α-SMA protein levels even after TGF-β1 stimulation (Fig. 7E). Lastly, we analyzed whether the reduction in collagen synthesis by activation of PPAR-β/δ and PPAR-γ depends on catalase activity. In both fibroblast cell lines, the reduction in collagen by the PPAR-γ agonist, but not by PPAR-β/δ was reversed in the presence of 3-amino-1,2,4-triazole (AT, Fig. 7F, lane 5 versus lanes 7 and 8). Interestingly, AT inhibited the beneficial effect of a combined activation of PPAR-β/δ and PPAR-γ in control, but not in IPF fibroblasts (Fig. 7F, lane 5 versus lane 6). We suggest that during TGF-β1 treatment either the protein level, sensitivity or signaling of PPAR-β/δ dominates in IPF and that of PPAR-γ in control fibroblasts with regard to catalase protein content and its activity.
Discussion
In the present study, cultured human lung fibroblasts were treated with TGF-β1 to mimic fibrosis and were then analyzed to evaluate the role of PPARs during disease progression. Human lung tissue samples from control and IPF patients (Figs. 1, 6) were used in parallel. Traditional animal models of experimental lung fibrosis were carried out by radiation or intratracheal administration of asbestosis fibers and silica, but the latter two induce rather asbestosis and silicosis than fibrosis [38]. Since high levels of TGF-β1 were shown to initiate and support fibrosis [35, 36], a rat model of adenoviral overexpression of TGF-β1 has been established, however, the adenovirus vector itself already induced fibrosis [38, 39]. Most commonly, mice were treated with bleomycin which induced a rapid fibrosis within 2–4 weeks via intra-tracheal instillation or 4–12 weeks by systemic administration [38]. The injury first triggers an inflammatory response which leads to wound healing. The infiltrating immune cells produce pro-fibrotic cytokines, e.g. TGF-β1, which stimulates fibroblast-to-myofibroblast transition. A dysregulated wound healing process could moreover lead to excessive deposition of ECM and finally resulting in fibrosis. However, this mouse model does not represent all aspects of the histopathological phenotype of the disease as observed in humans, for example, honeycomb pattern, thick scars at the alveolar region and fibroblastic foci [40,41,42], probably because these features take time to develop in humans. In addition, bleomycin-induced fibrosis is often reversible and contains a strong inflammatory component in the beginning which is not true for the disease in humans [38].
To mimic fibrosis in vitro, pro-fibrotic cytokines were added to cultured lung fibroblasts such as platelet-derived growth factor, connective tissue growth factor, interleukin-1β, tumor necrosis factor-α (TNF-α) and TGF-β1 [43]. Interleukin-1β and growth factors induced a marked inflammation and fibrosis with aberrant wound healing, TNF-α induced a strong inflammation and mild fibrosis, and TGF-β1 solely caused minor inflammation together with a marked fibrosis. Thus, TGF-β1-induced changes reflected the pathogenesis found in human IPF patients and was therefore used in our experiments. In vitro models, as an advantage, allow drug treatments to block TGF-β1-induced fibrosis signaling pathways and cell transfection to knockdown proteins of interest, which is difficult to establish in vivo. On the other hand, analysis of cultured lung fibroblasts neglects the in vivo situation where they interact with themselves and other cell types such as alveolar epithelial cells type I and type II, endothelial cells and macrophages. Interestingly, alveolar epithelial type II cells restrict the number of fibroblasts [44], and thus, control fibroblasts in vitro (and in the absence of alveolar epithelial type II cells) might re-start proliferation together with an increased collagen synthesis reaching similar levels as found in IPF fibroblasts. Moreover, TGF-β1 in IPF is mainly produced by macrophages [45]. Therefore, TGF-β1 (at least 5 ng/ml) had to be added to induce fibrosis in cultures of pure fibroblasts (which secrete 0.15 ng/ml TGF-β1, Fig. 1C). In this study, tissues and an in vitro model established with fibroblasts from control and IPF patients were used in parallel.
To study the pathophysiology of lung fibrosis, we measured the two fibrosis markers associated with IPF such as collagen [46,47,48], and α-SMA, although the latter has been currently debated as a sole marker for studying fibrosis [49] as its expression doesn´t mean that a cell produces high amounts of collagen [50]. Interestingly, IPF is characterized by excessive accumulation of collagen-rich ECM produced by activated fibroblasts and myofibroblasts [51, 52]; thus the degree of fibrosis is strongly dependent on their number and proliferation. Our data showed that fibroblasts from control and IPF patients were not different with regard to (1) the intracellular level of α-SMA and ω-fatty acids such as AA, DHA and EPA; (2) the release of collagen into the extracellular space; (3) the activity of collagen-degrading enzyme MMP-1; and (4) cell proliferation rate under basal conditions. Instead, fibroblasts from IPF compared to control patients showed significantly lower protein levels of PEX13, catalase, and of the TGFBR1 and are thus less sensitive towards TGF-β1. They secrete less active TGF-β1 into the culture medium. Contrarily, higher protein levels were found in IPF compared to control fibroblasts for intracellular GPX1/2 and PPAR-α. For IPF, the number and proliferation of fibroblasts/myofibroblasts are directly and the level of catalase indirectly related to the disease progression. Nonetheless, individual fibroblasts from control and IPF patients differ strongly even within the group (Figs. 1D, 6C, Additional file: Fig. S1A–C). This phenomenon might probably be due to the recently reported spatial heterogeneity of fibroblasts in fibrotic foci containing multiple subtypes such as lipofibroblasts, myofibroblasts, EBF1 + fibroblasts, intermediate fibroblasts, and mesothelial cells, all expressing different amounts of collagen under healthy conditions and during IPF progression [50]. In addition, the patients differ either with regard to the disease (acute exacerbation versus chronic stages, slow versus rapid decline of lung function), to co-morbidities (hypertension, viral infection, chronic aspiration of gastric content) or to other trigger factors such as age (age-related mitochondrial and peroxisomal dysfunction leading to oxidative stress), environmental exposures, smoking, and genetic factors [53]. Interestingly, differences between patients in our experiments were mainly observed for protein levels of PPAR-α (Fig. 1D), PPAR-γ (Fig. 1D), MMP-1 (Additional file: Fig. S1C) and catalase (Fig. 6C), whereas the protein levels of PPAR-β/δ (Fig. 1D), catalase activity (Fig. 6E), the level of intracellular and secreted collagen with and without TGF-β1 (Figs. 1B, 2B–D, Additional file: Fig. S1D) as well as the collagen-reducing effect of a combined treatment with PPAR-β/δ and PPAR-γ agonists (Fig. 3A–F) were less variable. This gives hope that the observed beneficial effect of PPAR-β/δ and PPAR-γ agonists is applicable to a broad spectrum of IPF patients. However, the strong heterogeneity of the target, namely the fibroblasts of IPF, but also of control patients, will limit the global use of any drug for IPF. Clinical trials discriminating between different subsets of patients may help to find the right drug in this regard.
We demonstrated that among the three PPARs, PPAR-β/δ might be a strong target for lung fibrosis resolution compared to PPAR-α (minor effect) and PPAR-γ (additive effect with PPAR-β/δ under these experimental conditions, Table 2). Focusing first on fibrosis pathways, we detected no differences between control and IPF fibroblasts with regard to the synthesis and release of collagen as well as gene expression and activity of MMP-1 (the dominant MMP, Fig. 4A) either when treated or untreated with TGF-β1, and PPAR-β and PPAR-γ agonists. However, MMPs differ between the diverse lung cell types such as alveolar epithelial type I and type II cells, alveolar macrophages and endothelial cells [54, 55]. In addition, MMP-1, -2, -3, -7, -13, -14, and -19, exhibit either anti- or pro-fibrotic [28] activities. MMP-2, as an example for the latter one, cleaves elastin which is deleterious for the lung. Interestingly, PPAR-β stimulation decreased the secretion of MMP-2 and increased the elastin level in human skin fibroblasts [56].
Next, we observed a TGF-β1-induced decrease in the peroxisomal biogenesis protein PEX13 which is reversed by stimulation of PPAR-γ. This was accompanied by changes in peroxisomal lipid metabolism, e.g. TGF-β1 increased the level of phosphatidylcholine in control, but decreased it in IPF fibroblasts with no additional effects of the PPAR drugs. The levels of AA, DHA and EPA were not significantly changed by TGF-β1, but increased strongly upon treatment with the PPAR-γ agonist. Metabolites from AA oxidation have been described to mediate inflammatory responses, and DHA is known to be anti-inflammatory [57, 58]. A balance between the fatty acids will essentially determine the direction of the drug interventions. The production of DHA was more than that of AA in control and IPF fibroblasts following PPAR-γ activation, whereas the activation of PPAR-β/δ increased levels of AA to a higher extent compared to DHA in control and IPF fibroblasts. However, the strong anti-fibrotic effects of PPAR-β/δ support the combined activation of both receptors during treatments. Thus, with regard to peroxisomes, PPAR-β/δ and PPAR-γ agonists increased the peroxisomal biogenesis protein PEX13, as well as peroxisome lipid metabolism, and the resulting metabolites may further activate PPARs, establishing a positive activation loop [59, 60].
Furthermore, the TGF-β1-induced decrease in the protein level and activity of catalase was reversed upon stimulation of PPAR-γ and PPAR-β/δ. Interestingly, in control fibroblasts the anti-fibrotic effect is mediated mainly via the maintenance of catalase protein through a reactive oxygen species (ROS)-dependent stimulation of PPAR-γ, because the effect is blocked by the specific catalase inhibitor AT in the combined treatment group by sustaining catalase levels. In IPF fibroblasts, the anti-fibrotic effect is mainly caused by a combined activation of PPAR-β/δ and PPAR-γ. The collagen-reducing effect is not inhibited by AT and thus ROS-independent. A decreased catalase level has been found in lung homogenates (and especially in the bronchial epithelium) of patients with IPF [61]. In acatalasemic mice, bleomycin induced a much higher invasion of pro-inflammatory cells together with increased levels of TGF-β1 and collagen and thus a higher degree of fibrosis [29], suggesting a beneficial role of high catalase levels in IPF disease progression. Interestingly, catalase (low affinity, high turnover) together with PRDX1 and PRDX5 (high affinity, low turnover), breakdown H2O2 generated by multiple pathways inside peroxisomes. While catalase is crucial for safeguarding the organelle at excessive H2O2, PRDX1 and PRDX5 function as a redox-regulator in cell signaling and H2O2 redox relay factor at low levels of H2O2, respectively [62]. In addition, catalase impedes ROS-induced inhibition of peroxisomal β-oxidation including the synthesis of the anti-inflammatory DHA [61]. With regard to PPARs, the catalase gene promotor region contains PPRE binding sites, e.g. for PPAR-γ (located at nucleotides − 1027 to − 1014; [63]) and an additional PPAR-γ binding site in humans only (located at nucleotides − 11,710 to − 11,698, [64]). Activation of PPAR-γ [23], but also of PPAR-β/δ (at the direct repeat 1 response element, [65]) increased catalase protein levels [65, 66]. We assume that the observed increase in catalase protein in our experiments by PPAR-β/δ and PPAR-γ was similarly due to an induction of the catalase promotor activity. The additive effect by the combined treatment with PPAR-β/δ and PPAR-γ ligands in IPF fibroblasts suggests an importance of the additional human-specific PPRE binding sites and demonstrates that human models are required to analyze the role of PPARs in fibrosis.
We would like to emphasize that in contrast to most of the previous publications we performed a post-treatment (to mimic the clinical situation) with a combination of PPAR-β/δ and PPAR-γ agonists to reverse the TGF-β1-induced fibrotic phenotype of IPF fibroblasts. It is well known that activated PPAR-γ alone is potentially anti-fibrotic [17,18,19,20]. With regard to PPAR-β/δ, to the best of our knowledge, only one review described an inhibition of the proliferation of normal human lung fibroblasts by its stimulation [26]. The question arises how an activation of PPAR-β/δ can support PPAR-γ or vice-versa. One possibility is that stimulation of one PPAR might increase the protein level of itself and of the other receptors. For example, agonists for PPAR-α and PPAR-β/δ, but not PPAR-γ, have been shown to increase the protein levels of PPAR-β/δ and PPAR-γ in osteoblasts [37]. Thus, especially PPAR-β/δ stimulation can end up in a positive activation loop as it increased its own as well as the PPAR-γ receptor [60]. This offers the possibility for a post-treatment schedule starting with the PPAR-β/δ agonist to increase PPAR-γ levels so that the later given PPAR-γ agonist can work more efficiently. Interestingly, after 48 h treatment with TGF-β1, we observed increases in the protein levels of PPAR-γ and PPAR-β/δ in control and IPF fibroblasts although with varying degrees (Fig. 2E, Table 1). This might explain why the post-treatment with PPAR-β/δ and PPAR-γ agonists is even more beneficial than direct treatment. Moreover, we demonstrated that the test compound STK 648389 (ZINC ID: 31,775,965), which has been suggested to be a dual PPAR-β/δ/PPAR-γ agonist by structure-based virtual screening [67], did not elicit anti-fibrotic effects (Additional file: Fig. S2). We hypothesized that the dual agonist (which is a single molecule) might be less specific for both receptors than the respective individual agonists and must be applied at a higher concentration which could induce more side effects in lung fibroblasts. Indeed, luciferase transactivation assays have shown EC50 values of 132 µM for PPAR-β/δ and 18 µM for PPAR-γ [67], and thus STK 648389 activated PPAR-γ only (see Fig. 3E showing no reduction of the extracellular collagen using 10 µM of the specific PPARγ agonist troglitazone).
In summary, combined activation of PPAR-β/δ and PPAR-γ exerts strong anti-fibrotic effects. Catalase, which is decreased during treatment with TGF-β1, is inverse proportionally involved in collagen production. Catalase protein level and activity can be increased by stimulation of PPAR-β/δ and PPAR-γ in control and IPF human lung fibroblasts. For IPF patients (to refer to the clinical situation), the most beneficial anti-fibrotic effects could possibly be achieved by a combined local treatment with PPAR-β/δ and PPAR-γ agonists via aerosol inhalation.
Availability of data and materials
Raw data of the lipid analyses are available upon request to the corresponding author.
Abbreviations
- α-SMA:
-
α-Smooth muscle actin
- AA:
-
Arachidonic acid
- AT:
-
3-Amino-1,2,4-triazole
- CAT:
-
Catalase
- COL1:
-
Collagen type 1
- DMEM:
-
Dulbecco’s Modified Eagle Medium
- DHA:
-
Docosahexaenoic acid
- ECM:
-
Extracellular matrix
- EPA:
-
Eicosapentaenoic acid
- GPX1/2:
-
Glutathione peroxidase 1/2
- HRP:
-
Horse radish peroxidase
- IPF:
-
Idiopathic pulmonary fibrosis
- LC–MS/MS:
-
Liquid chromatography tandem mass spectrometry
- MMP:
-
Matrix metalloproteinase
- MTBE:
-
Methyl-tert-butyl ether
- PC:
-
Phosphatidylcholine
- PE:
-
Phosphatidylethanolamine
- PEX:
-
Peroxisomal biogenesis protein, peroxin
- PPAR:
-
Peroxisome proliferator-activated receptor
- PRDX:
-
Peroxiredoxin
- PPRE:
-
PPAR response element
- ROS:
-
Reactive oxygen species
- RT-qPCR:
-
Quantitative reverse transcription polymerase chain reaction
- SM:
-
Sphingomyelin
- SPE:
-
Solid phase extraction
- TG:
-
Triglycerides
- TGF-β1:
-
Transforming growth factor-beta 1
- TGFBR1:
-
Transforming growth factor-beta receptor 1
- TNF-α:
-
Tumor necrosis factor-α
References
Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655–65. https://doi.org/10.1001/jama.2024.3669.
Cheresh P, Kim SJ, Tulasiram S, Kamp DW. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 2013;1832:1028–40. https://doi.org/10.1016/j.bbadis.2012.11.021.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82. https://doi.org/10.1056/NEJMoa1402584.
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47. https://doi.org/10.1164/rccm.202202-0399ST.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92. https://doi.org/10.1056/NEJMoa1402582.
Sofia C, Comes A, Sgalla G, Richeldi L. Promising advances in treatments for the management of idiopathic pulmonary fibrosis. Expert Opin Pharmacother. 2024;25:717–25. https://doi.org/10.1080/14656566.2024.2354460.
Bonella F, Spagnolo P, Ryerson C. Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs. 2023;83:1581–93. https://doi.org/10.1007/s40265-023-01950-0.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM, 1305-0013 Trial Investigators. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386:2178–87. https://doi.org/10.1056/NEJMoa2201737.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, Feldman J, Hajari Case A, Argula RG, Tapson V, Smith P, Deng C, Shen E, Nathan SD. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Eur Respir J. 2023;61:2202414. https://doi.org/10.1183/13993003.02414-2022.
Nathan SD, Behr J, Cottin V, Lancaster L, Smith P, Deng CQ, Pearce N, Bell H, Peterson L, Flaherty KR. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022;9: e001310. https://doi.org/10.1136/bmjresp-2022-001310.
Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, Minami M, Itoh Y, Okanoue T. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004;324:697–704. https://doi.org/10.1016/j.bbrc.2004.09.110.
Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond). 2002;103:S284–8. https://doi.org/10.1042/CS103S284S.
Oruqaj G, Karnati S, Vijayan V, Kotarkonda LK, Boateng E, Zhang W, Ruppert C, Günther A, Shi W, Baumgart-Vogt E. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-beta signaling. Proc Natl Acad Sci USA. 2015;112:2048–57. https://doi.org/10.1073/pnas.1415111112.
Oruqaj G, Karnati S, Kotarkonda LK, Boateng E, Bartkuhn M, Zhang W, Ruppert C, Günther A, Bartholin L, Shi W, Baumgart-Vogt E. Transforming growth factor-b1 regulates peroxisomal genes/proteins via Smad signaling in idiopathic pulmonary fibrosis fibroblasts and transgenic mouse models. Am J Pathol. 2023;193:259–74. https://doi.org/10.1016/j.ajpath.2022.11.006.
Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett. 2010;288:219–25. https://doi.org/10.1016/j.canlet.2009.07.006.
Ham SA, Kim HJ, Kim HJ, Kang ES, Eun SY, Kim GH, Park MH, Woo IS, Kim HJ, Chang KC, Lee JH, Seo HG. PPARdelta promotes wound healing by up-regulating TGF-beta1-dependent or -independent expression of extracellular matrix proteins. J Cell Mol Med. 2010;14:1747–59. https://doi.org/10.1111/j.1582-4934.2009.00816.x.
Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2005;288:L1146–53. https://doi.org/10.1152/ajplung.00383.2004.
Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ. Reddy RC PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L891–901. https://doi.org/10.1152/ajplung.00333.2007.
Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol. 2009;41:722–30. https://doi.org/10.1165/rcmb.2009-0006OC.
Lin Q, Fang LP, Zhou WW, Liu XM. Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res. 2010;36:120–8. https://doi.org/10.3109/01902140903214659.
El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, Szibor M, Kosanovic D, Schwind F, Schermuly RT, Henneke I, MacKenzie B, Quantius J, Herold S, Ntokou A, Ahlbrecht K, Braun T, Morty RE, Günther A, Seeger W, Bellusci S. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017;20:261-73.e3. https://doi.org/10.1016/j.stem.2016.10.004.
Speca S, Dubuquoy C, Rousseaux C, Chavatte P, Desreumaux P, Spagnolo P. GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE. 2021;16: e0257281. https://doi.org/10.1371/journal.pone.0257281.
Korbecki J, Bobiński R, Dutka M. Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors. Inflamm Res. 2019;68:443–58. https://doi.org/10.1007/s00011-019-01231-1.
Derrett-Smith E, Clark KEN, Shiwen X, Abraham DJ, Hoyles RK, Lacombe O, Broqua P, Junien JL, Konstantinova I, Ong VH, Denton CP. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Res Ther. 2021;23:234. https://doi.org/10.1186/s13075-021-02592-x.
Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017;76:1931–40. https://doi.org/10.1136/annrheumdis-2016-210821.
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The role of PPARs in lung fibrosis. PPAR Res. 2007;2007:71323. https://doi.org/10.1155/2007/71323.
Zeng Q, Zhou TT, Huang WJ, Huang XT, Huang L, Zhang XH, Sang XX, Luo YY, Tian YM, Wu B, Liu L, Luo ZQ, He B, Liu W, Tang SY. Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARgamma. Sci Rep. 2023;13:14706. https://doi.org/10.1038/s41598-023-41933-5.
Craig VJ, Zhang L, Hagood JS, Owen CA. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2015;53:585–600. https://doi.org/10.1165/rcmb.2015-0020TR.
Odajima N, Betsuyaku T, Nagai K, Moriyama C, Wang DH, Takigawa T, Ogino K, Nishimura M. The role of catalase in pulmonary fibrosis. Respir Res. 2010;11:183. https://doi.org/10.1186/1465-9921-11-183.
Smejkal GB, Kakumanu S. Enzymes and their turnover numbers. Expert Rev Proteomics. 2019;16:543–4. https://doi.org/10.1080/14789450.2019.1630275.
Filatova A, Seidel S, Böğürcü N, Gräf S, Garvalov BK, Acker T. Acidosis acts through HSP90 in a PHD/VHL-independent manner to promote HIF function and stem cell maintenance in glioma. Cancer Res. 2016;76:5845–56. https://doi.org/10.1158/0008-5472.CAN-15-2630.
Vijayan V, Srinu T, Karnati S, Garikapati V, Linke M, Kamalyan L, Mali SR, Sudan K, Kollas A, Schmid T, Schulz S, Spengler B, Weichhart T, Immenschuh S, Baumgart-Vogt E. A new immunomodulatory role for peroxisomes in macrophages activated by the TLR4 ligand lipopolysaccharide. J Immunol. 2017;198:2414–25. https://doi.org/10.4049/jimmunol.1601596.
Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008;49:1137–46. https://doi.org/10.1194/jlr.D700041-JLR200.
Garikapati V, Colasante C, Baumgart-Vogt E, Spengler B. Sequential lipidomic, metabolomic, and proteomic analyses of serum, liver, and heart tissue specimens from peroxisomal biogenesis factor 11a knockout mice. Anal Bioanal Chem. 2022;414:2235–50. https://doi.org/10.1007/s00216-021-03860-0.
Khalil N, O’Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991;5:155–62. https://doi.org/10.1165/ajrcmb/5.2.155.
Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, Hance AJ, Tazi A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J. 2003;22:69–76. https://doi.org/10.1183/09031936.03.00014703.
Qian G, Fan W, Ahlemeyer B, Karnati S, Baumgart-Vogt E. Peroxisomes in different skeletal cell types during intramembranous and endochondral ossification and their regulation during osteoblast differentiation by distinct peroxisome proliferator-activated receptors. PLoS ONE. 2015;10: e0143439. https://doi.org/10.1371/journal.pone.0143439.
Moore BB, Lawson WE, Tim Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49:167–79. https://doi.org/10.1165/rcmb.2013-0094TR.
Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest. 1997;100:768–76. https://doi.org/10.1172/JCI119590.
Fukuda Y, Basset F, Ferrans VJ, Yamanaka N. Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol. 1995;26:53–61. https://doi.org/10.1016/0046-8177(95)90114-0.
Cavazza A, Rossi G, Carbonelli C, Spaggiari L, Paci M, Roggeri A. The role of histology in idiopathic pulmonary fibrosis: an update. Respir Med. 2010;104:S11-22. https://doi.org/10.1016/j.rmed.2010.03.013.
Jones MG, et al. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight. 2016;1: e86375. https://doi.org/10.1172/jci.insight.86375.
Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des. 2003;9:39–49. https://doi.org/10.2174/1381612033392341.
Cerny L, Torday JS, Rehan VK. Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook. Lung. 2008;186:75–89. https://doi.org/10.1513/pats.201203-023AW.
Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9:111–6. https://doi.org/10.1513/pats.201203-023AW.
Nakos G, Adams A, Andriopoulos N. Antibodies to collagen in patients with idiopathic pulmonary fibrosis. Chest. 1993;103:1051–8. https://doi.org/10.1378/chest.103.4.1051.
Ramos C, Montaño M, García-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24:591–8. https://doi.org/10.1165/ajrcmb.24.5.4333.
Su Y, Gu H, Weng D, Zhou Y, Li Q, Zhang F, Zhang Y, Shen L, Hu Y, Li H. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (Baltimore). 2017;96: e6617. https://doi.org/10.1097/MD.0000000000006617.
Sun KH, Chang Y, Reed NI, Sheppard D. alpha-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGFbeta activation or collagen production across multiple models of organ fibrosis. Am J Physiol Lung Cell Mol Physiol. 2016;310:L824–36. https://doi.org/10.1152/ajplung.00350.2015.
Liu X, Dai K, Zhang X, Huang G, Lynn H, Rabata A, Liang J, Noble PW, Jiang D. Multiple fibroblast subtypes contribute to matrix deposition in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2023;69:45–56. https://doi.org/10.1165/rcmb.2022-0292OC.
Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol. 1994;145:114–25.
Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller DE. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 1996;271:31771–4. https://doi.org/10.1074/jbc.271.50.31771.
Gandhi S, Tonelli R, Murray M, Samarelli AV, Spagnolo P. Environmental causes of idiopathic pulmonary fibrosis. Int J Mol Sci. 2023;24:16481. https://doi.org/10.3390/ijms242216481.
Wallace AM, Sandford AJ, English JC, Burkett KM, Li H, Finley RJ, Müller NL, Coxson HO, Paré PD, Abboud RT. Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. COPD. 2008;5:13–23. https://doi.org/10.1080/15412550701817789.
Garcia-de-Alba C, Buendia-Roldán I, Salgado A, Becerril C, Ramírez R, González Y, Checa M, Navarro C, Ruiz V, Pardo A, Selman M. Expression of matrix metalloproteases by fibrocytes: possible role in migration and homing. Am J Respir Crit Care Med. 2010;182:1144–52. https://doi.org/10.1164/rccm.201001-0028OC.
Ham SA, Yoo T, Hwang JS, Kang ES, Lee WJ, Paek KS, Park C, Kim JH, Do JT, Lim DS, Seo HG. Ligand-activated PPARδ modulates the migration and invasion of melanoma cells by regulating Snail expression. Am J Cancer Res. 2014;4:674–82.
Tallima H, El Ridi R. Arachidonic acid: physiological roles and potential health benefits—a review. J Adv Res. 2018;11:33–41. https://doi.org/10.1016/j.jare.2017.11.004.
Meital LT, Windsor MT, Perissiou M, Schulze K, Magee R, Kuballa A, Golledge J, Bailey TG, Askew CD, Russell FD. Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages from patients with small abdominal aortic aneurysm. Sci Rep. 2019;9:12978. https://doi.org/10.1038/s41598-019-49362-z.
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318–23. https://doi.org/10.1073/pnas.94.9.4318.
Colasante C, Chen J, Ahlemeyer B, Baumgart-Vogt E. Peroxisomes in cardiomyocytes and the peroxisome/peroxisome proliferator-activated receptor-loop. Thromb Haemost. 2015;113:452–63. https://doi.org/10.1160/TH14-06-0497.
Hashimoto F, Hayashi H. Significance of catalase in peroxisomal fatty acyl-CoA beta-oxidation: NADH oxidation by acetoacetyl-CoA and H2O2. J Biochem. 1990;108:426–31. https://doi.org/10.1093/oxfordjournals.jbchem.a123217.
Fransen M, Lismont C. Peroxisomal hydrogen peroxide signalling: a new chapter in intracellular communication research. Curr Opin Chem Biol. 2024;78:102426. https://doi.org/10.1016/j.cbpa.2024.102426.
Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol. 2002;16:2793–801. https://doi.org/10.1210/me.2002-0020.
Okuno Y, Matsuda M, Miyata Y, Fukuhara A, Komuro R, Shimabukuro M, Shimomura I. Human catalase gene is regulated by peroxisome proliferator activated receptor-gamma through a response element distinct from that of mouse. Endocr J. 2010;57:303–9. https://doi.org/10.1507/endocrj.k09e-113.
Hur J, Kang ES, Hwang JS, Lee WJ, Won JP, Lee HG, Kim E, Seo HG. Peroxisome proliferator-activated receptor-delta-mediated upregulation of catalase helps to reduce ultraviolet B-induced cellular injury in dermal fibroblasts. J Dermatol Sci. 2021;103:167–75. https://doi.org/10.1016/j.jdermsci.2021.08.003.
Hwang JS, Kim E, Lee HG, Lee WJ, Won JP, Hur J, Fujii J, Seo HG. Peroxisome proliferator-activated receptor δ rescues xCT-deficient cells from ferroptosis by targeting peroxisomes. Biomed Pharmacother. 2021;143: 112223. https://doi.org/10.1016/j.biopha.2021.112223.
Maltarollo VG, Togashi M, Nascimento AS, Honorio KM. Structure-based virtual screening and discovery of new PPARd/g dual agonist and PPARd and g agonists. PLoS ONE. 2015;10: e0118790. https://doi.org/10.1371/journal.pone.0118790.
Acknowledgements
Many thanks to Petra Hahn-Kohlberger, Bianca Pfeiffer, Andrea Textor and Susanne Pfreimer for their outstanding technical assistance. Sincere gratitude to Dr. Eunsum Jung (Biospectrum Life Science Institute) and Prof. Marc Fransen (Université catholique de Louvain, Belgium) for providing the COL1A2 luciferase and catalase overexpression plasmids, respectively.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by funding from the German Academic Exchange Service (Government of Ghana DAAD, grant number 50015294) to EB, collaborative grant of the German Academic Exchange Service (DAAD) for granting the Graduate School Scholarship Programme "Lipids in Nutrition and Metabolism" (DAAD-GSSP-2015) to EBV, VG is a doctoral scholarship holder within this programme (Personal reference no 91566181), and performance-related resource allocation-funds of the Medical Faculty of the Justus Liebig University Giessen, so-called “Leistungsorientierte Mittel” (LOM) to EBV.
Author information
Authors and Affiliations
Contributions
E.B.-V., S.K. and E.B. conceived and designed the research studies; E.B., R.B, B.A., O.T., V.G. and M.R.A. conducted the experiments; E.B.-V., B.A., B.S., S.K., R.B., V.G., N.E-M. and E.B. acquired and analyzed the data analyzed; E.B.-V., S.K., M.S., B.S., C.R., G.O., and A.G. provided reagents and materials; and E.B.-V., B.A., R.B. and E.B. wrote the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Protocol, data collection and analysis of the human material (isolated lung fibroblasts, lung tissues) were approved by the Local Ethics Committee of the Justus Liebig University Giessen (Az58/15 and Az111/08, JLU).
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Eistine Boateng, Vannuruswamy Garikapati, Gani Oruqaj, Natalia El-Merhie, Srikanth Karnati: All experimental work has been done at Institute for Anatomy and Cell Biology, Division of Medical Cell Biology, Justus Liebig University, Aulweg 123, 35392, Giessen, Germany. Vannuruswamy Garikapati: The experimental work has been done in a cooperative project at two places at the JLU Giessen (Institute for Anatomy and Cell Biology, Division of Medical Cell Biology, Justus Liebig University and Institute of Inorganic and Analytical Chemistry, Justus Liebig University).
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Boateng, E., Bonilla-Martinez, R., Ahlemeyer, B. et al. It takes two peroxisome proliferator-activated receptors (PPAR-β/δ and PPAR-γ) to tango idiopathic pulmonary fibrosis. Respir Res 25, 345 (2024). https://doi.org/10.1186/s12931-024-02935-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12931-024-02935-7